IN8BIO, INC. 8-K

What Happened

• IN8bio, Inc. (INAB) filed an 8‑K on May 7, 2026 to announce its financial results for the quarter ended March 31, 2026 via a press release (furnished as Exhibit 99.1).
• At its May 7, 2026 annual meeting, stockholders approved the Amended and Restated 2026 Equity Incentive Plan (the “2026 Plan”), which replaces the 2023 plan and makes several changes to share availability and ISO rules. The full plan text is attached as Exhibit 10.1 to the 8‑K.

Key Details

• Quarterly period reported: quarter ended March 31, 2026; press release dated May 7, 2026 (Exhibit 99.1).
• The 2026 Plan increases the share reserve by 2,920,000 shares of common stock.
• The Annual Share Increase feature is extended through 2037 and is revised to include common stock issuable upon settlement of outstanding pre-funded warrants when calculating the annual increase.
• The plan sets a 20,000,000-share cap on shares that may be issued as incentive stock options (ISOs) and extends the outside grant date for ISOs to the 10th anniversary of the earlier of March 26, 2026 or the stockholder approval date.

Why It Matters

• The earnings press release provides the company’s latest quarterly results and is the primary source for short-term performance information investors use to assess momentum and financial health.
• Approval of the 2026 Plan increases the pool of shares available for employee and executive compensation (2.92M new shares) and extends annual automatic increases, which can lead to future dilution as awards are granted and exercised.
• The ISO cap and extended ISO grant window give the company greater flexibility to grant tax‑favored options to attract and retain employees and executives. Investors should watch future filings for the actual financial figures disclosed in the press release and for any grant activity that could affect fully diluted share count.